Probeer een andere zoekopdracht
571,19M
0,83%
16.04.2012
Naam | Titel | Sinds | Tot |
---|---|---|---|
Catherine Tennyson | - | 2024 | now |
Chris Eccles | Research Analyst | 2024 | now |
Biografie | Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector. Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist. Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford. | ||
Cinney Zhang | - | 2023 | now |
Linden Thomson | - | 1987 | 2024 |
Peter Hughes | Portfolio Manager | 2021 | 2023 |
Biografie | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
Dani Saurymper | - | 2015 | 2021 |
Biografie | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
Mark Hargraves | Portfolio Manager | 2014 | 2016 |
Biografie | Mark attended the University of Bristol gaining a Geography BSc (Hons). In 2000, he obtained a Masters in Finance from the London Business School. He is also a member of the UK Society of Investment Professionals. Mark spent two years working for Abbey National plc and then moved to Hambros Fund Management as assistant portfolio manager European Equities. In 1997, he joined United Friendly Asset Management as a fund manager for European Equities. Mark joined AXA Framlington as a fund manager in June 2000. | ||
Gemma Game | - | 2011 | 2014 |
Deane Donnigan | clinical Specialist | 1997 | 2011 |
Biografie | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
Antony Milford | - | 1987 | 2007 |
Weet u zeker dat u %USER_NAME% wilt blokkeren?
Als u dit doet, kunnen u en %USER_NAME% geen publicaties meer van elkaar zien op Investing.com.
%USER_NAME% is toegevoegd aan uw lijst met geblokkeerde personen
Omdat u de blokkering van deze persoon net hebt opgeheven, moet u 48 uur wachten om hem/haar weer te kunnen blokkeren.
Ik vind dit commentaar
Bedankt!
Uw bericht is ter beoordeling verstuurd naar de moderatoren